The Goal dIrected perFusion Trial in Cardiac Surgery

1. Study design Multicenter, international, prospective, randomized and controlled study. Patient population
2. Inclusion criteria: Adult (> 18 years) patients undergoing cardiac operations with CPB. Expected CPB duration > 90 minutes.
3. Exclusion criteria: severe chronic renal failure (dialysis or serum creatinine > 3.0 mg/dL); emergent (must be operated immediately) procedure; moderate-severe anemia (preoperative HCT < 32%); expected nadir CPB temperature < 32 °C.
4. Withdrawal criteria (after randomization): Need for allogeneic blood transfusions before CPB. Need for allogeneic blood to prime the CPB circuit. DHCA or other violations of the entry criteria. CPB duration below 90 minutes will not be withdrawal criterion, but a subroup analysis is anticipated.

Primary outcomes

Incidence of AKI, defined according to the AKIN criteria (9) as:

AKI stage 1: peak postoperative serum creatinine > 1.5 x baseline or absolute increase 0.3 mg/dL, within the first 48 hours after surgery.

AKI stage 2: peak postoperative serum creatinine > 2.0 x baseline, within the first 48 hours after surgery (AKI stage 3 will be incorporated in the AKI stage 2 group).

Any AKI: stage 1 or higher Peak serum creatinine: within the first 48 postoperative hours. Diagnosis of AKI must be reached within the first 48 hours after surgery, but staging may require a longer time (up to 7 days after surgery).

Secondary outcomes Length of ICU stay (days) Transfusion (red blood cells) rate and amount of red blood cells units transfused Major morbidity (according to STS): mechanical ventilation > 48 hours, AKI stage 2, surgical revision, mediastinitis, stroke.

Operative (in-hospital) mortality 3. Sample size The power analysis is based on the primary outcome "any AKI".

Data from the previous study (1) provide the following figures for the total patient population:

Any AKI rate: 21.2% AKI stage 1: 8.8% AKI stage 2-3: 12.4% With the following distribution according to a cut-off value settled at a nadir DO2 of 280 mL/min/m2.

Outcome All cases N=354 DO2 < 280 mL/min/m2 N= 181 DO2 ≥ 280 mL/min/m2 N= 173 P Any AKI 75 (21.2%) 54 (29.8%) 21 (12.1%) 0.001 AKI stage 1 31 (8.8%) 23 (12.7%) 8 (4.6%) 0.007 AKI stage 2-3 44 (12.4%) 31 (17.1%) 13 (7.5%) 0.006

Based on the above table, we know that the Control Group will spontaneously meet the goal in 50% of the cases, and that will have an any AKI rate of 21%.

We hypothesize that the Goal-Directed Perfusion (GDP) group will meet the goal in 95% of the cases. When the goal is met, the AKIN rate will be 12%; when it is not, it will be 29% This will lead to an expected AKI rate in GDP group of 12.8%.

Therefore, the effect size will be a 40% reduction in the AKI rate (12.8% in GDP group, 21% in Control group.

Based on this effect size, an alpha value of 0.05 and a beta value of 0.20, the number of patients in each group is 350, for a total patient population of 700.

Data analysis will be restricted to patients with a CPB duration > 60 minutes. Same applies to extremely long CPB duration, based on the percentile distribution of CPB.

Interim analyses planned at 25%, 50%, and 75% of patients enrollment, with stopping rules for futility, safety, efficacy. Stopping rule for futility: relative risk for the primary outcome not inclusing the hypothesized value of 0.6 within 99% confidence interval at 50% interim analysis or 95% at 75% interim analysis. Stopping rule for efficacy in presence of a difference in favour of the GDP arm at a P value of 0.01 at 25% interim analysis or 0.05 at the 50% and 75% interim analyses. Stopping rule for safety in presence of a difference in favor of the control arm at a P value of 0.01 at the 25% interim analysis or 0.05 at the 50% and 75% interim analyses (Ethics Committe amendment August 2016).

1. Interventions Patients will be randomly allocated to the Control or the GDP group. Randomization will be performed locally at each participating Institution, using computer-generated schemes.

The patients in control Group will be treated according to the local standards. The patients in GDP group will be treated according to the GDP (see table below).

CONTROL (N=350) TREATMENT (N=350) GDP monitor GDP monitor NO Blood prime (withdrawal) NO Blood prime (withdrawal) Priming volume and nature according to local standards Priming volume and nature according to local standards Perfusion targeted on body surface area and °C Perfusion targeted on DO2 ≥ 280 mL/min/m2 Perfusion pressure according to local standards Perfusion pressure according to local standards Transfusion triggered by HCT according to local standards Transfusion triggered by venous oxygen saturation < 68% and/or oxygen extraction rate > 40% Postoperative care according to local standards Postoperative care according to local standards

Details of the GDP protocol:

The main intervention to achieve the target value of DO2 is increasing the pump flow. Additional interventions include hemofiltration to increase the HCT.

Transfusion protocol

1. During CPB: Transfusions are mandatory below a HCT of 18%. Transfusions are generally prohibited for an HCT > 21%. However, based on the individual judgement that the patient is actually in need for packed red cells, transfusions are allowed between an HCT of 22% and 24%. In this case, this will be considered as a protocol violation, but the patient will not be withdrawn. Transfusions are always prohibited for an HCT > 24%.
2. After CPB: HCT < 18%: packed red cells are mandatory HCT between 19% and 23%: packed red cells are allowed HCT between 24% and 30%: packed red cells generally prohibited, but admitted based on physician's judgement. This represents a protocol violation. In this case, this will be considered as a protocol violation, but the patient will not be withdrawn.

HCT > 30%: packed red cells are prohibited.